Published in Health Business Week, May 22nd, 2009
“We currently have three novel agonists targeted to Toll-like Receptors in clinical development for different indications, two of which are being advanced and funded by our collaborators,” said Sudhir Agrawal, D.Phil., President, Chief Executive Officer and Chief Scientific Officer. “Additionally, we intend to submit an Investigational New Drug application by the end of 2009 for a fourth drug candidate, IMO-3100, which is a novel TLR antagonist for potential application in autoimmune diseases.”
“We ended the first quarter with $50.3...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.